ESC Premium Access

Novel strategies targeting residual risk: the promise of PCSK9 inhibiting therapies.

Topic: Inflammation and microcirculation
Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by unrestricted educational grants from Novartis and Amgen

Congress Presentation

About the speaker

Professor Erik Stroes

Academic Medical Centre, Amsterdam (Netherlands (The))
24 presentations
0 follower

4 more presentations in this session

Introduction - The post ACS patient and residual risk.

Speaker: Professor P. Libby (Boston, US)

Thumbnail

Inflammation as potential target for therapy to target residual risk post ACS.

Speaker: Doctor P. Ridker (Boston, US)

Thumbnail

Beyond statins: the role of ezetimibe in targeting residual risk.

Speaker: Professor C. Packard (Glasgow, GB)

Thumbnail

Discussion - How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation.

Speaker: Professor P. Libby (Boston, US) Professor J. Deanfield (London, GB)

Thumbnail

Access the full session

How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation

Speakers: Professor E. Stroes, Professor P. Libby, Doctor P. Ridker, Professor C. Packard, Professor P. Libby...
Thumbnail

About the event

Image

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk